Lite Strategy (NASDAQ:LITS - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Friday.
Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Lite Strategy in a report on Saturday, September 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of "Sell".
Check Out Our Latest Stock Analysis on LITS
Lite Strategy Price Performance
LITS stock traded down $0.12 on Friday, reaching $2.56. The company's stock had a trading volume of 1,507,643 shares, compared to its average volume of 1,740,819. Lite Strategy has a 52 week low of $1.46 and a 52 week high of $9.00.
About Lite Strategy
(
Get Free Report)
MEI Pharma, Inc, a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lite Strategy, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lite Strategy wasn't on the list.
While Lite Strategy currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.